Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET. Management will be available May 23rd throughout the day for virtual 1x1 meetings.

A webcast of the presentation may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Contact

investors@aclaristx.com